These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22191380)

  • 1. Neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorder.
    Wang LJ; Yeh CB; Huang YS; Tang CS; Chou WJ; Chou MC; Chen CK
    Nord J Psychiatry; 2012 Sep; 66(4):276-82. PubMed ID: 22191380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia.
    Yeh CB; Huang YS; Tang CS; Wang LJ; Chou WJ; Chou MC; Chen CK
    Nord J Psychiatry; 2014 Apr; 68(3):219-24. PubMed ID: 23795862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.
    Suppes T; Eudicone J; McQuade R; Pikalov A; Carlson B
    J Affect Disord; 2008 Apr; 107(1-3):145-54. PubMed ID: 17904226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.
    Tramontina S; Zeni CP; Ketzer CR; Pheula GF; Narvaez J; Rohde LA
    J Clin Psychiatry; 2009 Apr; 70(5):756-64. PubMed ID: 19389329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
    Keck PE; Orsulak PJ; Cutler AJ; Sanchez R; Torbeyns A; Marcus RN; McQuade RD; Carson WH;
    J Affect Disord; 2009 Jan; 112(1-3):36-49. PubMed ID: 18835043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
    Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
    J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder.
    Youngstrom E; Zhao J; Mankoski R; Forbes RA; Marcus RM; Carson W; McQuade R; Findling RL
    J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):72-9. PubMed ID: 23480324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline.
    Sachs GS; Gaulin BD; Gutierrez-Esteinou R; McQuade RD; Pikalov A; Pultz JA; Sanchez R; Marcus RN; Crandall DT
    J Clin Psychiatry; 2007 Sep; 68(9):1377-83. PubMed ID: 17915976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
    Keck PE; Marcus R; Tourkodimitris S; Ali M; Liebeskind A; Saha A; Ingenito G;
    Am J Psychiatry; 2003 Sep; 160(9):1651-8. PubMed ID: 12944341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
    Sachs G; Sanchez R; Marcus R; Stock E; McQuade R; Carson W; Abou-Gharbia N; Impellizzeri C; Kaplita S; Rollin L; Iwamoto T;
    J Psychopharmacol; 2006 Jul; 20(4):536-46. PubMed ID: 16401666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.
    Barzman DH; DelBello MP; Kowatch RA; Gernert B; Fleck DE; Pathak S; Rappaport K; Delgado SV; Campbell P; Strakowski SM
    J Child Adolesc Psychopharmacol; 2004; 14(4):593-600. PubMed ID: 15662152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.
    Zeni CP; Tramontina S; Ketzer CR; Pheula GF; Rohde LA
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):553-61. PubMed ID: 19877980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.
    Findling RL; Correll CU; Nyilas M; Forbes RA; McQuade RD; Jin N; Ivanova S; Mankoski R; Carson WH; Carlson GA
    Bipolar Disord; 2013 Mar; 15(2):138-49. PubMed ID: 23437959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respondent and item level patterns of response of aripiprazole in the acute treatment of pediatric bipolar I disorder.
    Findling RL; Youngstrom EA; Zhao J; Marcus R; Andersson C; McQuade R; Mankoski R
    J Affect Disord; 2012 Dec; 143(1-3):231-5. PubMed ID: 23044285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder.
    Biederman J; Mick E; Spencer T; Doyle R; Joshi G; Hammerness P; Kotarski M; Aleardi M; Wozniak J
    CNS Spectr; 2007 Sep; 12(9):683-9. PubMed ID: 17805214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
    Mankoski R; Zhao J; Carson WH; Mathew SJ; Forbes RA
    J Child Adolesc Psychopharmacol; 2011 Aug; 21(4):359-64. PubMed ID: 21823911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
    Brown ES; Jeffress J; Liggin JD; Garza M; Beard L
    J Clin Psychiatry; 2005 Jun; 66(6):756-60. PubMed ID: 15960570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.
    El-Mallakh RS; Marcus R; Baudelet C; McQuade R; Carson WH; Owen R
    J Affect Disord; 2012 Feb; 136(3):258-66. PubMed ID: 22209190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.